Autonomic Nervous System and Meridian Energy in Patients With Schizophrenia
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-65
SponsorNational Taiwan University Hospital
About this trial
This study aims to explore the differences in autonomic nervous function and meridian energy between schizophrenia patients and healthy individuals. By understanding the meridian and organ conditions of individuals, the study aims to align with the traditional Chinese medicine (TCM) concept of "treating disease before it arises" and provide comprehensive care to patients, thereby improving the quality of care.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Disease group：
Diagnosed with schizophrenia by a physician (ICD-10 code F20, such as F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, or F20.9), with stable condition, and has not had any changes in medication dosage or admission to a psychiatric acute care unit in the past 3 months.
Aged between 18 and 65 years.
Able to understand, speak, read, and write Mandarin or Taiwanese.
Disqualifiers
Disease group：
Individuals with cardiovascular conditions, severe neurological disorders (e.g., organic brain disorders, early-stage dementia or diagnosed dementia), or substance abuse issues.
Individuals who have used medications affecting the autonomic nervous system within the past month, such as mood stabilizers, antidepressants, angiotensin-converting enzyme inhibitors inhibitors, β-blockers, or antiarrhythmics.
Individuals with metallic implants that could affect heart rate variability.
Trial population
1. Disease group(schizophrenia):According to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), individuals who meet the criteria for a diagnosis of schizophrenia. 2. Control group(healthy individuals):No history of chronic illness in the past and no acute symptoms within the past month.
Trial design
Design model
Other
Time perspective
Cross-sectional
Treatments tested in this trial
no intervention
Other interventionno intervention
Treatment groups
100 Participants
are divided into 2 treatment groupsGroup A: schizophrenia1 intervention
Group B: healthy individuals1 intervention
Trial outcomes
Primary outcomes
1
meridian energy
Measuring the body energy under static balance conditions using principles of electromagnetic induction technology.The measurement items include:lung meridian (LU), large intestine meridian (LI), stomach meridian (ST), spleen meridian (SP), heart meridian (HT), small intestine meridian (SI), bladder meridian (BL), kidney meridian (KI), pericardium meridian (PC), triple burner meridian (SJ), gallbladder meridian (GB), liver meridian (LR)
Time frame
This study is a cross-sectional study with a single follow-up. Participants who meet the inclusion criteria will be included in the study, with a recruitment period of one year.2
heart rate variability
Assessing autonomic nervous system activity through the measurement of RR intervals. The measurement items include: the square root of the mean squared differences of successive NN intervals , NN50 count divided by the total number of all NN intervals, HRV triangular index, low frequency power, high frequency power, LF/HF Ratio, total power
Time frame
This study is a cross-sectional study with a single follow-up. Participants who meet the inclusion criteria will be included in the study, with a recruitment period of one year.Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov